**Core tip:** There are few reviews concerning the feasibility of using marginal liver grafts in living donor liver transplantation (LDLT). We reviewed more than 300 articles, summarized new findings, and confirmed that marginal grafts are a feasible option for expanding options for patients on liver transplant waiting lists in emergency situations in LDLT (*e.g*., liver failure or hepatic encephalopathy). However, such grafts place the recipients at greater risk for adverse events. Although some indispensable treatments are needed to address the deficiencies of these grafts, recipients can receive a favorable prognosis, similar to that of patients who receive standard liver grafts, under these treatments.

INTRODUCTION
============

The high mortality of patients on waiting lists due to the shortage of cadaveric donors is a major challenge in liver transplantation (LT)\[[@B1]\]. This challenge has led to the emergence of living donor liver transplantation (LDLT) after the first successful procedure in 1989\[[@B2],[@B3]\]. However, following a sharp increase in recipients who suffer from emergency situations, the wide gap between the demands of patients and suitable living donors is gradually increasing\[[@B4],[@B5]\]. Therefore, the transplantation community has focused on the search for strategies to increase the pool of available liver grafts, including the use of organs that were previously considered "unusable" by many and often labeled "marginal" organs\[[@B6]\].

An accepted definition of marginal donors remains unclear in LDLT. These expanded-criteria grafts have the potential to increase the risk of poor graft function or primary nonfunction and are referred to as "marginal" organs\[[@B7]\]. In this review, we define marginal liver grafts for LDLT as small-for-size grafts, older donors, moderate or severe steatosis of liver grafts, chronic hepatitis, and grafts with tumors. The survival of recipients with marginal organs can be the same as that of patients with high-quality liver grafts under proper treatment\[[@B8]\].

Many previous studies have reported on the possibilities of using marginal grafts in orthotopic liver transplantation (OLT), but there is still a lack of discussion on this topic, especially regarding the feasibility of using marginal grafts in LDLT. Therefore, the present review aimed to summarize and discuss the possibility of expanding the application of marginal grafts in LDLT.

SMALL-FOR-SIZE GRAFTS IN LDLT
=============================

Choosing to use a liver graft can be a remarkably complex decision. There is an increasing trend of patients dying while on waiting lists due to the everyday risk of death or serious complications while waiting; this risk must be balanced against the use of a marginal graft, which may not be feasible. Size mismatching between the graft and the recipient is a critical predictor of the so-called "marginal liver grafts" in LDLT recipients. A small-for-size graft has become the main reason for unsuitability for liver donation in some transplantation centers\[[@B9]\]. The most common index with which to evaluate graft size matching is the graft-to-recipient weight ratio (GRWR) or graft volume (GV)/standard liver volume (SLV). The GRWR was first reported to require a safety range of above 1%; otherwise, the rate of graft survival could decrease\[[@B10]\]. With the increased demand for LDLT and the improvement of surgical techniques, however, many expanded-criteria grafts are used. Accordingly, the accepted arbitrary requirement for GRWR was reduced to 0.8%, and the GV/SLV value was 40%\[[@B11],[@B12]\]. As many transplantation centers accumulated experience on small-for-size grafts for LDLT, grafts with a GRWR \< 0.8% were used and reported to be as safe as those with a GRWR ≥ 0.8%\[[@B13]-[@B17]\]. After challenging the boundary of GRWR = 0.8%, the acceptable minimum GRWR has been continuously lowered. Lee SD et al\[[@B18]\] reported that a GRWR as low as 0.7% is safe and that there is no need to modulate portal pressure in adult-to-adult LDLT using the right-lobe in favorable conditions, such as a low Model for End-Stage Liver Disease (MELD) score. Furthermore, Alim A et al\[[@B19]\] even suggested that a GRWR as low as 0.6% may be safe if the MELD score is \< 20, donor age is \< 45, and there is no evidence of liver steatosis in the donor graft during portal inflow modulation performed according to the portal flow. To date, the reported lowest GRWR of grafts that have been successfully used is between 0.40% and 0.46% (Table [1](#T1){ref-type="table"})\[[@B20]\].

###### 

Recommended minimum graft-to-recipient weight ratio in different studies

  **Ref**.                         **Recommended minimum GRWR**            ***n* (small *vs* large)**   **One-year survival (small *vs* large)**                                                                                                       **Five-year survival (small *vs* large)**   **Study type**
  -------------------------------- --------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ----------------
  Kiuchi et al\[[@B10]\] (1999)    1%                                      276 (49 *vs* 215)            61.2% *vs* 92.6%                                                                                                                               NS                                          RS
  Lee et al\[[@B11]\] (2003)       0.8%                                    141 (10 *vs* 131)            Univariate and multiple analysis                                                                                                               NS                                          RS
  Moon et al\[[@B13]\] (2010)      Less than 0.8%                          427 (35 *vs* 392)            87.8% *vs* 90.7%                                                                                                                               74.1% *vs* 79.4%                            RS
  Lan et al\[[@B14]\] (2009)       Less than 0.8%                          89 (15 *vs* 74)              73.3% *vs* 71.6%                                                                                                                               NS                                          RS
  Selzner et al\[[@B15]\] (2009)   Less than 0.8%                          271 (22 *vs* 249)            91.0% *vs* 89.0%                                                                                                                               83.0% *vs* 87%                              RS
  Chen et al\[[@B16]\] (2014)      Less than 0.8%                          196 (45 *vs* 151)            82.2% *vs* 81.4%                                                                                                                               71.1% *vs* 75.5%                            RS
  She et al\[[@B17]\] (2017)       Left lobe graft *vs* right lobe graft   218 (19 *vs* 199)            89.5% *vs* 95.9%                                                                                                                               89.5% *vs* 86.8%                            RS
  Lee et al\[[@B18]\] (2014)       Less than 0.7%                          317 (23 *vs* 294)            100% *vs* 93.2%                                                                                                                                NS                                          RS
  Alim et al\[[@B19]\] (2016)      0.6%                                    649                          Seven patients had GRWR of 0.6%. If MELD score was below 20, donor age below 45, and no signs for any hepatosteatosis, GRWR of 0.6% was safe   RS                                          
  Lee et al\[[@B20]\] (2015)       0.40%                                   NS                           Lowest GRWR of 0.40% had been successfully used                                                                                                RS                                          

PS: Prospective study; RS: Retrospective study; Ref.: Reference; GRWR: Graft-to-recipient weight ratio.

Small-for-size syndrome (SFSS), including small-for-size dysfunction (SFSD) and small-for-size nonfunction (SFSNF), is a concerning and life-threatening complication in patients receiving grafts with a GRWR \< 0.8%\[[@B21],[@B22]\]. The incidence of SFSS varies from 4.7% to 27.5% in different LT centers\[[@B23]-[@B30]\]. Specifically, the syndrome rate can be as high as 50%-75% in left-lobe LDLT or small-for-size grafts group and as low as 8.4% in right-lobe LDLT\[[@B31],[@B32]\]. Graft size is the only independent predictor of SFSS\[[@B31]\]. However, other studies have described that SFSS can occur even in the presence of a normal GRWR\[[@B16]\]. Regardless of the definition used for SFSS, it seems clear that other key factors should be considered in addition to a mismatched graft size. The incidence of SFSS is listed in Table [2](#T2){ref-type="table"}.

###### 

Incidence of small-for-size syndrome when using small-for-size grafts *n* (%)

  **Ref**.                              ***n***   **SFSS (Incidence)**   **Factors to SFSS**                                                                        **Study type**
  ------------------------------------- --------- ---------------------- ------------------------------------------------------------------------------------------ ----------------
  Goldaracena et al\[[@B21]\] (2017)    NS        NS                     A graft GRWR \< 0.8% of predisposes the graft to SFSS                                      RE
  Graham et al\[[@B22]\] (2014)         NS        NS                     GRWR of 0.8 to 1.0 was established as a lower limit to prevent SFSS                        RE
  Botha et al\[[@B23]\] (2010)          21        1 (4.7)                Hemi-portocaval shunt can decrease SFSS incidence                                          RS
  Goralczyk et al\[[@B24]\] (2011)      22        5 (22.7)               Posterior cavoplasty can decrease SFSS incidence                                           RS
  Soejima et al\[[@B25]\] (2003)        36        8 (22.2)               Cirrhosis predisposes the graft to SFSS                                                    RS
  Ben-Haim et al\[[@B26]\] (2001)       40        5 (8)                  Child's class B or C with received grafts of GRWR \< 0.85% predisposes the graft to SFSS   RS
  Sudhindran et al\[[@B27]\] (2012)     NS        10%-20%                Left lobe grafts predisposes the graft to SFSS                                             RE
  Yi et al\[[@B28]\] (2008)             29        8 (27.5)               Left lobe grafts predisposes the graft to SFSS                                             RS
  Soejima et al\[[@B29]\] (2012)        312       43 (15.3)              Left lobe grafts predisposes the graft to SFSS                                             RS
  Gruttadauria et al\[[@B30]\] (2015)   83        13 (15.7)              Non-surgical modulation of the portal inflow can decrease SFSS incidence                   RS
  Shoreem et al\[[@B31]\] (2017)        174       20 (11.5)              Left lobe grafts predisposes the graft to SFSS                                             RS
  Lauro et al\[[@B32]\] (2007)          8         4 (50)                 Surgical modulation of the portal inflow can decrease SFSS incidence                       RS

RE: Review; RS: Retrospective study; SFSS: Small-for-size syndrome; GRWR: Graft-to-recipient weight ratio.

Middle hepatic vein (MHV) or outflow reconstruction of the liver graft is associated with size mismatch. A small-for-size graft without MHV reconstruction can lead to various degrees of congestion of the anterior segment and a greater loss of hepatocellular function\[[@B33]\]. In our early observational studies with small sample sizes, we recommended a GRWR \> 1.0%\[[@B34]\] or even 1.2%\[[@B35]\] as a security threshold for patients without MHV reconstruction. Asakuma M et al\[[@B36]\] established an algorithm known as the estimated congestion ratio (ECR, ECR = regional volume of v5 + v8 / right-lobe volume) to estimate whether MHV should be reconstructed for low-GRWR grafts. A liver with an ECR \> 0.4 is an MHV-dominant liver, and higher GRWR grafts should be used. However, it is still unknown how far we can lower the GRWR following the improvement of postoperative management and surgical technique if there is no reconstruction of outflow. In addition to outflow reconstruction, the inflow of grafts, including portal hypertension following reperfusion and the hyperdynamic splanchnic state, is reported as a major factor that can trigger SFSS\[[@B37]-[@B39]\]; however, these views are controversial\[[@B40]\]. Enhanced cholestasis, hepatocyte ballooning, disruption of the sinusoidal line, and transformation of activated Ito cells into fibroblasts are observed under the conditions of portal hypertension, or overperfusion\[[@B41],[@B42]\]. Recipients with a final portal vein pressure (PVP) ≤ 15 mmHg or a pressure gradient of PVP-central vein pressure (CVP) ≤ 5 mmHg have a better prognosis\[[@B43]\]. In another study, liver-graft-to-spleen-volume ratio was used to predict early graft function in children and young adults undergoing LDLT, in which \< 0.88 predicted portal hyperperfusion\[[@B44]\]. Moreover, a MELD score \> 20\[[@B45]\], a decline in the platelet (PLT) count at post operation day (POD) 3 \> 56%\[[@B46]\] and donor age \> 45 years are also risk factors for a poor prognosis in recipients of small-for-size grafts\[[@B19]\].

To increase the safety of the expanded use of small-for-size grafts, some treatments are recommended. Graft inflow or PVP modulation is at the forefront of these treatments. Portosystemic shunting techniques or preservation of collateral veins\[[@B19],[@B47]-[@B50]\], as well as splenectomy or splenic artery ligation/embolization\[[@B51]-[@B53]\], are effective ways to address post-transplantation portal hyperperfusion. In cases where the GRWR of grafts is very low, dual grafts can be considered\[[@B54]\]. Moreover, autologous stem cell implantation\[[@B55]\] and auxiliary partial LDLT (a second transplant) are also reported to treat SSFS\[[@B56]\]. Remedies when using small-for-size grafts are listed in Table [3](#T3){ref-type="table"}.

###### 

Remedies when using small-for-size graft

  **Ref**.                            ***n***   **Remedy for using small-for-size graft**                                                                                       **Study type**
  ----------------------------------- --------- ------------------------------------------------------------------------------------------------------------------------------- ----------------
  Botha et al\[[@B23]\] (2010)        21        Hemi-portocaval shunt can decrease SFSS incidence                                                                               RS
  Goralczyk et al\[[@B24]\] (2011)    22        Posterior cavoplasty can decrease SFSS incidence                                                                                RS
  Kim et al\[[@B47]\] (2017)          160       Preserving collateral veins on small-for-size grafts                                                                            RS + PSM
  Hessheimer et al\[[@B48]\] (2011)   NS        Portocaval shunt                                                                                                                AE
  Xiao et al\[[@B49]\] (2012)         1         Transjugular intrahepatic portosystemic shunt                                                                                   CR
  Sato et al\[[@B50]\] (2008)         4         Portocaval shunt using ligamentum teres                                                                                         CR
  Nutu et al\[[@B51]\] (2018)         2         Complete splenic embolization                                                                                                   CR
  Badawy et al\[[@B52]\] (2017)       164       Splenectomy                                                                                                                     RS
  Troisi et al\[[@B53]\] (2016)       NS        Splenic artery ligation, splenectomy, meso-caval shunt, spleno-renal shunt, portocaval shunt, and splenic artery embolization   SR
  Xu et al\[[@B54]\] (2015)           NS        Dual grafts                                                                                                                     RE
  Gao et al\[[@B55]\] (2017)          NS        Adipose-derived mesenchymal stem cells tranplantation                                                                           AE
  Kobayashi et al\[[@B56]\] (2009)    5         Auxiliary partial liver transplantation                                                                                         CR

PSM: Propensity score matching; AE: Animal experiments; CR: Case report; SR: Systematic review; RE: Review; SFSS: Small-for-size syndrome.

Generally, a GRWR \< 0.8% is no longer a critical predictor for recipients and can even be lowered to 0.5%-0.6% if there are accompanying factors of PVP ≤ 15 mmHg, MHV reconstruction, or young donor age.

OLDER DONORS IN LDLT
====================

Because LDLT allows more choices in the use of a suitable liver graft compared with OLT, elderly donors were rarely considered in the early years of transplantation. However, following the increasing demands for LDLT and the urgent need to save the lives of patients suffering from hepatic encephalopathy, the use of elderly liver grafts has been reported more frequently in recent years as a means to increase the donor pool and address high waiting list mortality\[[@B57]\]. In Japan, the percentages of donors older than 50 and 60 years were 18.1% and 4%, respectively\[[@B58]\]. It is expected that the number of older donors will increase in the future because of the continuing donor shortage\[[@B59]\].

The definition of older donors is quite different in different transplantation centers. In the present review, we define older donors as donors older than 50 years. Controversy exists regarding the use of livers from older donors. The liver regeneration rate is impaired in older donors (donor age ≥ 50 years) compared with young donors (donor age \< 30 years), according to computed tomography (CT) volumetric data after LDLT at POD 7\[[@B60]\], and donor age (≥50 years) was independently correlated with impaired remnant liver regeneration at 3\[[@B61]\] and 6 mo in right-lobe LDLT\[[@B58]\]. Kawano Y et al\[[@B62]\] analyzed telomeres in the hepatocytes of 12 paired donor-recipients and found that donor age was a crucial factor affecting the sustainability of telomere length in hepatocytes after pediatric LDLT. Based on the conclusion that older donors were significantly associated with impaired liver regeneration, some researchers found that the recipients of grafts from donors older than 45-50 years old, along with a GW/SLV ratio \< 35%-40%, had worse outcomes\[[@B63],[@B64]\]. Yoshizumi T et al\[[@B65]\] established the following formula, called a predictive score, to evaluate the impact of donor age, graft size, and MELD score on prognosis: predictive score = 0.011 × graft weight (%) - 0.016 × donor age - 0.008 × MELD score - 0.15 × shunt (if present) - 1.757. Patients with a predictive score ≥ 1.3 had a lower incidence of postoperative complications and a better prognosis.

Additionally, more studies have shown that LDLT using older donors could induce more serious postoperative complications and higher mortality rates than transplants using younger donors\[[@B66]-[@B70]\]; similarly, having a donor older than the recipient by \> 20 years is problematic\[[@B68]\]. Moreover, it has been reported that fibrosis progression in patients with recurrent hepatitis C tended to be faster after LDLT with grafts from older donors\[[@B71]\]. Donor age is an independent, strong prognostic factor in LDLT. However, other researchers found that grafts from older donors can be used safely, even though the regenerative capacity of older grafts is impaired when the donor age is ≥ 50 years\[[@B72]-[@B75]\] or even ≥ 55 years\[[@B76]\]. The impact of older donors on the 1- and 5-year survival of recipients is shown in Table [4](#T4){ref-type="table"}.

###### 

Older donors for living donor liver transplantation

  **Ref**.                             **Definition of older donors**       ***n* (older *vs* young)**   **One-year survival (older *vs* young)**                                                                     **Five-year survival (older *vs* young)**   **Study type**
  ------------------------------------ ------------------------------------ ---------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------- ----------------
  Tanemura et al\[[@B58]\] (2012)      50 yr old                            101 (24 *vs* 77)             Older donor livers might have impaired regenerative ability                                                  RS                                          
  Ono et al\[[@B60]\] (2011)           50 yr old                            15 (6 *vs* 9)                Liver regeneration is impaired with age after donor hepatectomy                                              RS                                          
  Akamatsu et al\[[@B61]\] (2007)      50 yr old                            299 (62 *vs* 237)            85.0% *vs* 93.0%                                                                                             72.0% *vs* 87.0%                            RS
  Kawano et al\[[@B62]\] (2014)        NS                                   12                           Donor age is a crucial factor affecting telomere length sustainability in hepatocytes after pediatric LDLT   PS                                          
  Imamura et al\[[@B63]\] (2017)       NS                                   198                          A worse outcome might be associated with aging of the donor                                                  RS                                          
  Dayangac et al\[[@B64]\] (2011)      50 yr old                            150 (28 *vs* 122)            78.6% *vs* 83.4%                                                                                             NS                                          RS
  Yoshizumi et al\[[@B65]\] (2008)     NS                                   28                           Graft size, donor age, and patient status are the indicators of early graft function                         RS                                          
  Han et al\[[@B66]\] (2014)           55 yr old                            604 (26 *vs* 578)            Median OS (M): 31.2 ± 31.3 *vs* 50.6 ± 40.6                                                                  RS                                          
  Kamo et al\[[@B67]\] (2015)          60 yr old                            1597 (69 *vs* 1528)          69.5% *vs* 81.2%                                                                                             62.0% *vs* 79.3%                            RS
  Shin et al\[[@B68]\] (2013)          Donor-recipient age gradient \> 20   821                          Worse graft survival was observed if the donor is older than the recipient by \> 20                          RS                                          
  Kubota et al\[[@B69]\] (2017)        50 yr old                            315 (126*vs* 189)            73.0% *vs* 80.9%                                                                                             39.7% *vs* 47.1%                            RS
  Katsuragawa et al\[[@B70]\]          NS                                   24                           G/SLV and donor age were independent factors that affected graft survival rates                              RS                                          
  Wang et al\[[@B72]\] (2015)          50 yr old                            159 (10 *vs* 149)            100% *vs* 93.0%                                                                                              90.0% *vs* 87.0%                            RS
  Ikegami et al\[[@B73]\] (2008)       50 yr old                            232 (32 *vs* 200)            80.0% *vs* 81.7%                                                                                             73.8% *vs* 76.7%                            RS
  Li et al\[[@B74]\] (2012)            50 yr old                            129 (21 *vs* 108)            90.0% *vs* 86.0%                                                                                             66.0% *vs* 75%                              RS
  Goldaracena et al\[[@B75]\] (2016)   50 yr old                            469 (91 *vs* 378)            92.0% *vs* 96.0%                                                                                             83.0% *vs* 79.0%                            RS
  Kim et al\[[@B76]\] (2017)           55 yr old                            540 (42 *vs* 498)            95.2% *vs* 94.6%                                                                                             NS                                          RS

LDLT: Living donor liver transplantation; CR: Case report; RS: Retrospective study.

While donor age is a controversial topic, the impaired regenerative capacity of older grafts has been confirmed in some studies. According to these previous studies, older liver grafts can be prudent candidates but cannot be used in the presence of other marginal conditions (*e.g*., small-for-size grafts or moderate and severe steatosis). More high-quality and prospective studies are needed on this topic.

ABO-INCOMPATIBLE LDLT
=====================

Although more high-quality liver grafts are available for patients in LDLT than in OLT, donors are restricted to family members or domestic relationships in many transplantation centers because of ethical norms. ABO-incompatible LTs are performed only in emergencies, when ABO-compatible grafts are unavailable. Therefore, breaking ABO blood group barriers becomes inevitable. ABO-incompatible LT was first performed and reported by Starzl et al\[[@B77]\], and no acute rejections were observed after transplantation. Subsequently, ABO-incompatible LT gradually began to be performed in some LT centers, and hyperacute rejection was commonly reported\[[@B78],[@B79]\].

In addition to antibody-mediated rejection, ABO-incompatible LDLT can involve other complications. Thrombotic microangiopathy (TMA) is a rare complication following LT, but it is reported to have a slightly higher incidence in ABO-incompatible LDLT\[[@B80]-[@B82]\]. ABO incompatibility, cyclophosphamide and recipient blood group (type O) are closely correlated with the occurrence of TMA\[[@B80],[@B82]\]. The incidence of TMA is 37.9% following ABO-incompatible LDLT and 0.0%-2.8% following ABO-compatible LDLT (OR = 44.7)\[[@B80]\]. The elevation of fibrinolytic function markers, such as plasminogen activator inhibitor type 1, can be considered a predictor of TMA following LDLT. The incidence of biliary tract complications is more common than that of TMA. Biliary strictures are one of the most important complications associated with ABO incompatibility, with reported incidence rates between 15.8% and 20.7%\[[@B83],[@B84]\]. An isoagglutinin attack on the graft vascular endothelium can result in ischemic cholangiopathy, and isoagglutinin can even directly attack the endothelium of the graft bile duct\[[@B85],[@B86]\]. CT scans can provide a clear indication of biliary strictures in ABO-incompatible LDLT\[[@B87]\]. Yamada Y et al\[[@B88]\] reported a case of idiopathic hypereosinophilic syndrome following ABO-incompatible LDLT. The patient suffered from portal vein thrombosis on postoperative day 10, and the histopathological findings of the thrombus revealed dense eosinophilic deposition. Studies on the impact of ABO incompatibility on LDLT are listed in Table [5](#T5){ref-type="table"}.

###### 

Impact of ABO-incompatible on living donor liver transplantation

  **Ref**.                         ***n***   **Complications**              **Incidence of related complication (%)**   **Risk factors**                                               **Study type**
  -------------------------------- --------- ------------------------------ ------------------------------------------- -------------------------------------------------------------- ----------------
  Miyata et al\[[@B80]\] (2007)    57        Thrombotic microangiopathy     7.0                                         ABO-incompatibility, CPA, and recipient blood group (type O)   RS
  Oya et al\[[@B81]\] (2008)       1         Thrombotic microangiopathy     NS                                          ABO-incompatible LDLT (type B to O)                            CR
  Kishida et al\[[@B82]\] (2016)   129       Thrombotic microangiopathy     10.1                                        ABO-incompatible, tacrolimus                                   RS
  Song et al\[[@B83]\] (2014)      1102      Biliary stricture              15.8                                        ABO-incompatible, acute cellular rejection                     RS
  Ikegami et al\[[@B84]\] (2016)   408       Biliary stricture              20.4                                        ABO-incompatible                                               RS
  Yamada et al\[[@B88]\] (2010)    1         Idiopathic hypereosinophilic   NS                                          ABO-incompatible                                               CR

LDLT: Living donor liver transplantation; CR: Case report; RS: Retrospective study.

Despite serious complications, ABO-incompatible LDLT can be a feasible option for patients if certain essential treatments are included\[[@B89],[@B90]\]. Rituximab, an anti-CD20 immunoglobulin (IgG)1 terminating B-lymphocytes with an affinity for IgG Fc receptor (FcγR), is a critical strategy in the regimens for desensitization for ABO-incompatible LDLT and yields outcomes for ABO-incompatible LDLT that are similar to those for ABO-compatible LDLT\[[@B91],[@B92]\]. Rituximab is given for 3 d\[[@B93]\], 3 wk, or even as soon as a suitable donor that is ABO-compatible is selected\[[@B94]\] at a dosage of 375 mg/m^2^. In the early stage of transplantation, rituximab was usually given along with one or more other protocols, such as a splenectomy\[[@B95],[@B96]\], plasma exchanges\[[@B97]-[@B102]\], intravenous IgG\[[@B100],[@B103]\], and intrahepatic arterial infusion of prostaglandin E1\[[@B92],[@B104],[@B105]\]. In some recent studies, pre-transplant rituximab and/or basiliximab monotherapy, without additional treatments, also yielded outcomes that are comparable to those of procedures with additional treatments\[[@B106]\]. The affinity between IgG Fcγ Receptor (FcγR) and rituximab, however, is influenced by the single-nucleotide polymorphisms (SNPs) of FcγR. SNPs of FCGR2A (131H/R) and FCGR3A (158F/V) are the alleles that encode FcγR. FCGR2A (131H/H) had a higher affinity for IgG1 than FCGR2A (131H/R or R/R). Accordingly, patients with FCGR2A (131H/H) have a better reaction to the effects of rituximab on B cells\[[@B91]\]. The treatment results of ABO-compatible LDLT are summarized in Table [6](#T6){ref-type="table"}.

###### 

Remedies when using ABO- incompatible on living donor liver transplantation

  **Ref**.                            ***n***   **Immunosuppression strategy**   **Remedies**                                                     **Conclusion**                                                                                     **Study type**
  ----------------------------------- --------- -------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------
  Kawagishi et al\[[@B89]\] (2009)    105       TAC + MP + AZ                    Rituximab                                                        ABO-incompatible LDLT can be feasible used if humoral rejection are overcome                       RS
  Yoon et al\[[@B90]\] (2018)         918       TAC + MP + steroids              Rituximab and PE                                                 ABO-incompatible LDLT is a feasible option under remedies                                          RS
  Sakai et al\[[@B91]\] (2017)        20        TAC+ MP                          Rituximab and PE                                                 FCGR SNPs influence the effect of rituximab on B-cells                                             PS
  Egawa et al\[[@B92]\] (2017)        33        TAC                              Rituximab, PE, local infusion, splenectomy and immunoglobulins   Only rituximab dose is a significantly favorable factor for AMR                                    RS
  Ikegami et al\[[@B93]\] (2007)      1         TAC + MP + steroids              Rituximab and PE                                                 Rituximab and plasma exchanges seemed ineffective                                                  CR
  Ikegami et al\[[@B94]\] (2009)      7         TAC + MP + steroids              Rituximab, IVIG, and PE                                          Rituximab, IVIG, and PE seems to be a safe treatment                                               RS
  Usui et al\[[@B95]\] (2007)         73        TAC + MP + steroids              Rituximab, PE and splenectomy                                    Bone suppression is a big challenge when using rituximab                                           RS
  Chen et al\[[@B96]\] (2017)         2         TAC + MP + steroids              Basiliximab combine with splenectomy                             ABO-i LDLT with splenectomy is undoubtedly life-saving                                             CR
  Uchiyama et al\[[@B97]\] (2011)     15        TAC + MP + steroids              Rituximab and PE                                                 Isoagglutinin mediated-rejection should be more concerned                                          RS
  Soin et al\[[@B98]\] (2014)         3         TAC + MP + steroids              Rituximab and PE                                                 ABO-incompatible LDLT is a feasible option under remedies                                          CR
  Rummler et al\[[@B99]\] (2017)      10        TAC + MP + steroids              PE                                                               Immunosuppression only combining with PE is feasible                                               RS
  Kim et al\[[@B100]\] (2016)         182       TAC + MP + steroids              Rituximab, IVIG, and PE                                          ABO-incompatible LDLT can be safely performed under remedies                                       RS
  Kim et al\[[@B101]\] (2013)         22        TAC + MP + steroids              Rituximab and PE                                                 ABO-incompatible LDLT can be safely performed under remedies                                       RS
  Kawagishi et al\[[@B102]\] (2005)   3         TAC + MP + steroids              Rituximab and PE                                                 ABO-incompatible LDLT can be safely performed under remedies                                       CR
  Kim et al\[[@B103]\] (2017)         43        TAC + MP + steroids              Rituximab and IVIG                                               A simplified protocol using rituximab and IVIG for ABO-I LDLT is safe                              RS
  Yoshizawa et al\[[@B104]\] (2005)   8         TAC + MP + cyclophosphamide      Rituximab and PGE1 infusion                                      Rituximab prophylaxis and HA infusion therapy is feasible                                          RS
  Egawa et al\[[@B105]\] (2008)       118       TAC + steroids                   Methylprednisolone and PGE1 infusion                             Recipients with preexisting high effector CD8 T- cells are unfavorable candidates for ABO-I LDLT   RS
  Yamamoto et al\[[@B106]\] (2018)    40        TAC + MP + steroids              Rituximab monotherapy                                            Rituximab monotherapy is feasible                                                                  RS

LDLT: Living donor liver transplantation; CR: Case report; RS: Retrospective study; SNPs: Single-nucleotide polymorphisms.

These findings reveal that rituximab monotherapy in ABO-compatible LDLT is feasible, but it is better to test the SNPs of FcγR; otherwise, multiple treatments, such as plasma exchanges and intravenous IgG, must be performed in addition to rituximab if there is a lower affinity between IgG FcγR and rituximab. There is still a lack of more persuasive evidence to confirm the feasibility of splenectomy in conjunction with ABO-compatible LDLT treatments.

LIVER GRAFT STEATOSIS
=====================

Steatosis is a common feature used to identify marginal liver function, and reports on the utility of steatotic liver grafts in clinical practice have yielded controversial results. The use of steatotic liver grafts has been confirmed to have a significant relationship with increased complications and poorer outcomes\[[@B107],[@B108]\]. Traditionally, steatotic livers with \> 60% fat must be discarded. Livers with \< 30% fat are feasible and anticipated to have good function. Livers with 30%-60% fat have poor results, with decreased graft survival and decreased patient survival\[[@B109]\]. Moreover, hepatic steatosis is reported to be a leading cause of donor rejection in LDLT\[[@B110]\]. In some transplantation centers, approximately 40% of donor grafts are discarded because of severe liver steatosis\[[@B9]\]. Because of the release of inflammatory cytokines and inhibition of the capacity to differentiate steatosis hepatocytes, the early regenerative capacity of the remnant liver is injured, and, as a result of impaired hepatocyte replication, compensatory expansion of hepatic progenitor cells occurs during steatotic liver regeneration after LDLT\[[@B111]\]. Furthermore, Cho et al\[[@B112]\] confirmed that hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after LDLT. In this study, 67 LDLT recipients examined on POD 10 were scored based on the numbers of portal tracts per area of liver tissue and intrahepatic cholestasis, and the preoperative degree of macrovesicular steatosis was found to be independently associated with cholestasis after LDLT. However, these researchers also found that the long-term capacity of hepatocyte regeneration was not impaired after LDLT with mild macrovesicular steatosis grafts\[[@B113]\]. Based on this finding, some recent studies have found that moderately steatotic liver grafts and donors with a BMI ≥ 30 kg/m^2^ are not contraindications for LDLT, and complications and survival are not significantly different compared with those associated with non-steatosis grafts\[[@B114],[@B115]\]. Moreover, the risk of steatosis was determined by the presence of microsteatosis and macrosteatosis, rather than the total quantitative degree of steatosis. The grafts with high microsteatosis (30%) mixed with macrosteatosis showed no significant difference in postoperative biochemical liver function, 2-wk graft regeneration, postoperative complications, and 5-year survival\[[@B116]\]. The studies on the impact of graft steatosis on LDLT outcomes are listed in Table [7](#T7){ref-type="table"}.

###### 

Impact of graft steatosis on living donor liver transplantation

  **Ref**.                          ***n***   **Conclusion**                                                                                                                                                          **Study type**
  --------------------------------- --------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Dirican et al\[[@B9]\] (2015)     161       Approximately 40% of donor grafts are discarded because of severe liver steatosis                                                                                       RS
  Perkins et al\[[@B109]\] (2006)   NS        Typically steatotic livers with \> 60% fat are not transplanted; with \< 30% fat are usable and anticipated to have good function; with 30%-60% fat give poor results   Comments
  Kotecha et al\[[@B110]\] (2013)   340       Hepatic steatosis is a leading cause of donor rejection in LDLT                                                                                                         PS
  Cho *et a*\[[@B111]\]*l* (2010)   54        Hepatocyte replication is impaired during steatotic liver regeneration after LDLT                                                                                       PS
  Cho et al\[[@B112]\] (2006)       67        Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration                                                      PS
  Cho et al\[[@B113]\] (2005)       55        Mildly steatotic graft did not increase the risk of graft dysfunction or morbidity in LDLT                                                                              PS
  Gao et al\[[@B114]\] (2009)       24        Moderately steatotic (30%-60%) liver grafts provide adequate function in the first phase after transplantation and can be used for transplantation                      RS
  Knaak et al\[[@B115]\] (2017)     105       Donors with BMI \> 30, in the absence of graft steatosis, are not contraindicated for LDLT                                                                              RS
  Han et al\[[@B116]\] (2015)       211       The risk of steatosis may be determined by the relative composition of MiS and MaS, rather than the total quantitative degree                                           RS

LDLT: Living donor liver transplantation; RS: Retrospective study; PS: Prospective study.

To decrease the risk associated with fatty liver grafts, especially with severe steatosis, some treatments are suggested (Table [8](#T8){ref-type="table"}). According to Oshita et al\[[@B117]\], donors who are diagnosed with hepatic steatosis pre-transplantation should undergo a diet treatment consisting of an 800-1400 kcal/d diet and a 100-400 kcal/d exercise regimen without drug treatment with a target body mass index of 22 kg/m². After these strategies, the average BMI was reduced from 23.3 ± 0.6 to 21.9 ± 0.4 kg/m². The liver biopsy results of most of these donors showed stage 0/1 fibrosis and minimal/mild steatosis after the diet therapy. In addition, surgical outcomes and overall survival did not significantly differ between the recipients of grafts from non-steatosis and diet-treated donors (with steatosis). In another study, bezafibrate (400 mg/d) was used along with a protein-rich (1000 kcal/d) diet and exercise (600 kcal/d) for 2-8 wk\[[@B118]\]. Even severely steatotic livers could be used for LDLT grafting subsequent to this short-term treatment regimen. Furthermore, a 1200 kcal/d diet and a minimum of 60 min/d of moderate cardio training are also recommended to rapidly reverse liver steatosis in donors\[[@B119]\]. In addition to lifestyle and dietary changes, dual-graft LDLT was reported when one donor had severe liver steatosis and another had a low GRWR\[[@B120]\].

###### 

Treatments for fat donors

  **Ref**.                            ***n***   **Treatments**                                                                                                                                                   **Study type**
  ----------------------------------- --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Oshita et al\[[@B117]\] (2012)      128       Diet treatment consisting of an 800 to 1400 kcal/d diet and a 100 to 400 kcal/d exercise regimen without drug treatment, targeting body mass index of 22 kg/m²   RS
  Nakamuta et al\[[@B118]\] (2013)    11        Bezafibrate (400 mg/d) was used along with a protein-rich (1000 kcal/d) diet and exercise (600 kcal/d) for 2-8 wk                                                RS
  Choudhary et al\[[@B119]\] (2015)   16        1200 kcal/d and a minimum of 60 min/d of moderate cardio training are also recommended to rapidly reverse liver steatosis in donors                              PS
  Moon et al\[[@B120]\] (2006)        2         Dual-graft living donor liver transplantation for severe graft steatosis                                                                                         CR

RS: Retrospective study; PS: Prospective study; CR: Case report.

In conclusion, steatosis in the donor must be thoroughly evaluated before LDLT, either by biopsy or imaging diagnosis. The proportion of macrosteatosis is now considered a crucial predictor of the prognosis of recipients. If there are no further options, donors with hepatic steatosis can reach donation criteria through lifestyle and dietary changes in a short time.

CHRONIC HEPATITIS OF GRAFTS
===========================

The use of liver grafts that test positive for chronic hepatitis or other blood disseminated diseases found in epidemic areas is usually inevitable in cases of organ shortages associated with OLT. However, because LDLT recipients, to some degree, have more choices regarding his/her donors, there are a few studies reporting on HBsAg or HBcAb(+) liver grafts, while no studies refer to HCV-positive living liver grafts.

HBsAg(-) LDLT patients who have received HBsAg or HBcAb(+) grafts have a high risk of *de novo* HBV infection after transplantation (Table [9](#T9){ref-type="table"}). However, these grafts are still considered to be safe and feasible with antiviral prophylaxis in both adult and pediatric LDLT\[[@B121]-[@B126]\]. Patients were given HBV vaccinations to achieve anti-HBs \> 1000 IU/L pre-transplantation and \> 100 IU/L post-transplantation, with a standard post-transplantation treatment regimen of high-dose hepatitis B IgG, lamivudine and/or adefovir (in cases of lamivudine resistance)\[[@B126]\]. Specifically, some studies have proposed a new strategy; specifically, patients with a pre-transplantation anti-HB titer \> 1000 IU/L do not need post-transplantation prophylaxis; patients with a low pre-transplantation titer, \< 1000 IU/L, should be given lamivudine post-transplantation (at a dose of 100 mg/d or 3 mg/kg/d for at least 2 years after transplantation) or adefovir prophylaxis (with lamivudine at a dose of 10 mg/d if a mutant strain for lamivudine is identified) and, hopefully, will respond appropriately to post-transplantation vaccinations by maintaining anti-HB titers \> 100 IU/L; and low titer non-responders (anti-HB titer \< 100 IU/L despite vaccination) should be given continuous lamivudine or adefovir indefinitely\[[@B121]\]. In some transplantation centers, nucleotide analogs (lamivudine) are routinely used first if HBsAg(-) LDLT patients receive HBsAg or HBcAb(+) grafts, regardless of the anti-HB titer, for at least 2 years. Moreover, patients who had a YMDD mutation were given adefovir combined with lamivudine\[[@B123]\]. Hara Y et al\[[@B127]\] reported one patient who experienced spontaneous eradication of *de novo* HBV after LDLT with an HBcAb(+) graft without any treatment. This 8-year-old female patient (HBsAg-negative) underwent LDLT, received an HBcAb(+) left-lobe graft, and was subsequently infected with HBV. Sixteen years after LDLT, her serological HBV status was as follows: HbsAg(-), HBsAb(+), HBeAb(-), HBeAb(+), HbcAb(+), and HBV DNA(-). In another study, recipients with HCV genotype 2 infections who had received an HBcAb(+) graft were given sofosbuvir and ribavirin, along with hepatitis B IgG to prevent recurrence of HCV and HBV\[[@B128]\].

###### 

Impact of HBsAg or HBcAb(+) grafts on HBsAg(-) living donor liver transplantation patients

  **Ref**.                        **Donor**   **Incidence of *de novo* HBV infection (%)**   **Prevention of *de novo* HBV infection**                                                                                             **Study type**
  ------------------------------- ----------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Wang\[[@B121]\] (2017)          HBcAb(+)    4.2                                            HBV vaccinations with the aim of achieving anti-HBs \> 1000 IU/L pre-transplant and \> 100 IU/L post-transplant                       RS
  Xi et al\[[@B122]\] (2013)      HBcAb(+)    23.9                                           No prophylaxis, adefovir, and lamivudine are given to *de novo* patients                                                              RS
  Dong et al\[[@B123]\] (2017)    HBcAb(+)    7.9                                            HBIG 100 IU/kg during the operation and lamivudine 3 mg/kg per day after the surgery for at least 1 year until HBV vaccine reaction   RS
  Loggi et al\[[@B124]\] (2016)   HBsAg(+)    NS                                             HBIG and lamivudine, adefovir or tenofovir                                                                                            SR
  Lei et al\[[@B125]\] (2013)     HBcAb(+)    15.0                                           No specific prophylaxis                                                                                                               RS
  Lin et al\[[@B126]\] (2007)     HBcAb(+)    3.3                                            Lamivudine monoprophylaxis, HBV vaccinations                                                                                          RS
  Hara et al\[[@B127]\] (2016)    HBcAb(+)    NS                                             Lamivudine first and adefovir dipivoxil were combined with lamivudine 2 yr later                                                      CR

HBV: Hepatitis B virus; RS: Retrospective study; SR: Systematic review; CR: Case report.

In HbsAg(+) LDLT patients who receive HBsAg or HBcAb(+) grafts, the antiviral protocol must be performed as for HBsAg(-) LDLT patients to maintain the HBV DNA at a low or negative level, despite the persistence of the HBV marker (HBsAg). High-dose HBV IgG, lamivudine, famciclovir, and interferon were recommended (Table [10](#T10){ref-type="table"})\[[@B129]-[@B131]\].

###### 

Impact of HBsAg or HBcAb(+) grafts on HBsAg(+) living donor liver transplantation patients

  **Ref**.                          **Donor**   **Incidence of *de novo* HBV infection**   **Prevention of De Novo HBV infection**                                                                 **Study type**
  --------------------------------- ----------- ------------------------------------------ ------------------------------------------------------------------------------------------------------- ----------------
  Hwang et al\[[@B129]\] (2006)     HBsAg(+)    NS                                         High-dose HBIG and lamivudine, famciclovir and interferon; a final regimen of lamivudine and adefovir   CR
  Soejima et al\[[@B130]\] (2007)   HBsAg(+)    NS                                         lamivudine and adefovir dipivoxil                                                                       CR
  Jeng et al\[[@B131]\] (2015)      HBsAg(+)    NS                                         Entecavir 0.5 mg once daily                                                                             RS

HBV: Hepatitis B virus; CR: Case report; RS: Retrospective study.

Populations with HBsAg-negative/HBcAb-positive and undetectable serum HBV DNA have been gradually increasing over the past several decades. Most patients are now considered to have a covert HBV infection and have a high risk of HBV reactivation when treated with a robust immunosuppressive agent\[[@B132]\]. Therefore, the use of HBsAg-negative/HBcAb-positive liver grafts has a high risk of *de novo* HBV for HBsAg(-) recipients. However, with active immunization and an antiviral protocol, the HBsAg-negative/HBcAb-positive liver grafts can be transplanted safely.

GRAFTS WITH A BENIGN HEPATIC TUMOR
==================================

Usually, there are rare recipients of LDLT or doctors who are willing to make an active choice to use a graft with an undetermined tumor. This is not only an ethical issue but also indicates a high risk for recipients to face rapid dysfunction of their liver grafts. However, if recipients are in an emergency situation and have no other proper donors, grafts with benign tumors may be a last choice. Li G et al\[[@B133]\] recently reported on 15 consecutive recipients using an otherwise discarded, partial liver resection graft with a benign hepatic tumor. These benign tumors are as follows: Cavernous hemangioma, perivascular epithelioid cell tumor, inflammatory pseudotumor, and focal nodular hyperplasia. One patient died from a pulmonary embolism, and the other 14 patients had a good prognosis. Additionally, a vanishing tumor in a liver graft from an HBV(+) donor was observed. Contrast-enhanced magnetic resonance imaging (MRI) showed hypervascularity in the arterial phase and in the hepatobiliary phase, the tumor showed a low intensity, findings similar to those in HCC. Regardless, the graft with suspected HCC was accepted by the recipient, and the tumor disappeared completely within several months after LDLT\[[@B134]\].

For LDLT patients using grafts with a benign hepatic tumor, only two observational studies with a small sample size are present in the literature (Table [11](#T11){ref-type="table"}). It seems that grafts with benign tumors are feasible in some conditions, but more studies with long-term follow-ups are needed to evaluate the safety of these marginal grafts.

###### 

Graft with hepatic benign tumor

  **Ref**.                          ***n***   **Type of tumors in grafts**                                                                                         **Prognosis**                              **Study type**
  --------------------------------- --------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------
  Li et al\[[@B133]\] (2017)        15        Cavernous hemangioma, perivascular epithelioid cell tumor, inflammatory pseudotumor, and focal nodular hyperplasia   One patient died from pulmonary embolism   OS
  Fuchino et al\[[@B134]\] (2017)   1         HBsAg(+) and inflammatory pseudotumor                                                                                Tumor vanished after 3 yr                  CR

OS: Observational study; CR: Case report.

CONCLUSION
==========

To our knowledge, this is the first review on marginal donors specifically for LDLT. This review, which includes cohort studies, case-control studies, and case reports on marginal liver grafts in LDLT, demonstrated that marginal grafts are a feasible way to expand the options for patients on LT waiting lists in emergency situations (*e.g*., liver failure or hepatic encephalopathy); however, these grafts place the recipients at a greater risk of liver dysfunction. Some indispensable treatments are needed to address the deficiencies of these grafts.

There are some new findings in this review: (1) It is permissible for the GRWR to be as low as 0.5%-0.6% (not 0.8%, as currently specified) if PVP is controlled under 15 mmHg; otherwise, outflow reconstruction is needed. (2) There is controversy surrounding older liver grafts. These grafts can be used prudently, but other marginal conditions must be absent (*e.g*., small-for-size grafts or moderate and severe steatosis). (3) Splenectomy is no longer necessary when an ABO-incompatible LDLT is performed. Rituximab monotherapy is even confirmed to be an effective treatment if there is a high affinity between IgG FcγR and rituximab. (4) Total steatosis of liver grafts is not a proper predictor of prognosis. Instead, the presence of microsteatosis and macrosteatosis is a crucial factor. Donors with steatosis of the liver can meet the donation criteria through lifestyle and dietary changes before surgery. (5) HbsAg or HbcAb(+) grafts increase the risk of *de novo* HBV infection after transplantation in HBsAg(-) LDLT patients but can also be used safely with active immunotherapy. And (6) Grafts with benign tumors that have been discarded from other patients are feasible, but the long-term prognosis cannot be determined.

According to the new findings of this review listed above, we summarized a selection of strategies for different types of marginal liver grafts in LDLT and their related treatments (Figure [1](#F1){ref-type="fig"}). With this review, based on more than 100 references, we expect that the transplantation pool can be effectively and safely expanded in the situation of organ shortage.

![Selective strategies and remedies of using marginal donors in living donor liver transplantation.](WJG-24-2441-g001){#F1}
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